iSpecimen stock gets reverse-split approval, ratio still open

iSpecimen shareholders approved an authorization for a reverse stock split at the company's reconvened meeting on October 30, according to an 8-K filing reproduced by StockTitan. The authorization covers a ratio ranging from 1-for-10 to 1-for-100, while the board will determine the final ratio.

Vote Sets Next Corporate Decision

The proposal received 1,152,016 votes in favor, 142,944 against and 868 abstentions. Abstentions had no effect under the approval standard, and no broker non-votes were reported.

A total of 1,295,828 shares were present in person or by proxy at the October 30 meeting, representing approximately 51.5 percent of the shares entitled to vote. The vote therefore cleared the authorization, but it did not specify when the reverse split will take effect or which ratio the board will select.

For investors, the next company announcement matters more than the authorization alone. The chosen ratio, effective date and any related Nasdaq compliance considerations will determine how the corporate action changes the number of shares outstanding and the per-share quotation.

Marketplace Focus And Competition

iSpecimen operates a technology-enabled marketplace that connects life science researchers with patients, human biospecimens and related data through healthcare-provider networks, according to its investor overview. Its offering covers access to human biofluids, tissue and cells for research, serving biopharmaceutical, diagnostic, academic and government users.

The company is based in the United States and remains a specialized marketplace provider within the broader diagnostics and research-services industry. Its position is defined more by specimen procurement and matching technology than by the large-scale laboratory testing model used by broader healthcare research suppliers.